查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1912604

自动化核酸合成市场：依技术、通量、产品类型、应用和最终用户划分－2026-2032年全球预测

Automatic Nucleic Acid Synthesizer Market by Technology, Throughput, Product Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，自动化核酸合成仪市值将达到 4.6527 亿美元，到 2026 年将成长至 5.0932 亿美元，到 2032 年将达到 8.8027 亿美元，年复合成长率为 9.53%。

关键市场统计数据
基准年 2025 4.6527亿美元
预计年份：2026年 5.0932亿美元
预测年份 2032 8.8027亿美元
复合年增长率 (%) 9.53%

本书权威地介绍了自动化核酸合成技术及其在现代研究、临床诊断和治疗开发中的重要角色。

自动化核酸合成仪已从一种罕见的专用桌上型仪器发展成为现代生命科学工作流程中不可或缺的一部分。这些平台能够自动产生寡核苷酸，简化引子、探针、小干扰RNA和合成基因的生成流程，而这些正是研究、诊断和治疗开发的基础。随着分子生物学技术在学术界、临床和工业界的日益普及，按需可靠地产生客製化序列的能力已成为追求敏捷性和可重复性的机构的核心竞争力。

小型化、模组化自动化和整合软体的融合如何重塑核酸合成领域的买方期望、供应商策略和营运模式

随着技术、营运和市场力量的融合，自动化核酸合成领域正经历着快速而变革性的转变。小型化和微流体控技术的进步使得更紧凑的合成装置成为可能，并促进了现场合成的普及；而平行化和机器人技术则扩展了高通量发现工作流程的容量。这些技术进步与固相化学和纯化策略的改进相辅相成，降低了错误率，并拓宽了使用者可用的化学方法选择。

评估2025年关税趋势和贸易政策转变如何重塑核酸合成设备生态系统的供应链、采购时机和製造策略

2025年关税政策的变化为核酸合成设备价值链上的相关人员带来了新的挑战。影响进口零件、仪器组件和特殊耗材的关税调整，使得供应链韧性问题日益凸显，迫使製造商和采购商重新评估筹资策略和营运缓衝。为此，一些製造商正加强推进关键供应链的在地化，在多个地区寻找替代供应商，并提高库存透明度，以缓解潜在的前置作业时间波动。

详细的細項分析揭示了技术架构、最终用户优先顺序、应用需求、吞吐量需求和产品类型如何驱动购买决策和产品蓝图。

对市场区隔的详细分析揭示了技术和使用者主导的显着动态，这些动态塑造了产品设计、服务模式和市场推广策略。基于技术，平台可分为基于色谱柱的架构和基于薄膜的架构，两者在合成精度、週期时间和放大难度方面各有优劣。基于色谱柱的系统通常着重于成熟的化学方法和批次一致性，而基于薄膜的设计则可在特定应用中提供通量和并行性方面的优势。

对美洲、欧洲、中东和非洲以及亚太市场进行全面的区域分析，包括推动市场接受度的因素、监管方面的细微差别以及影响市场需求的商业策略。

区域趋势对核酸合成产业的技术应用、监管要求和商业策略有显着影响。在美洲，学术研究中心、生物技术丛集以及完善的合约研究生态系统支撑了对柔软性的桌上型和可扩展的机器人解决方案的需求。该地区的监管环境和报销机制进一步推动了对诊断和治疗研发的投资，刺激了对检验的工作流程和供应商协助实施服务的需求。

竞争情报和策略定位洞察，揭示产品生态系统、伙伴关係和售后服务如何为设备製造商和整合商打造制胜之道。

自动化核酸合成领域的竞争动态体现了成熟仪器产品组合与敏捷的新兴企业之间的平衡，后者专注于透过软体、耗材和服务实现差异化。领先供应商凭藉其整合的耗材生态系统、检验的通讯协定以及全球支持，在法规环境下降低了准入门槛，从而保持了竞争优势。同时，新兴企业专注于微流体技术、新型固体相载体以及以用户为中心的软体等细分创新，以加快特定应用的实验结果获取速度。

为製造商、供应商和机构买家提供切实可行的策略建议，以增强其韧性，实现服务差异化，并推动不同终端用户采用其产品和服务。

产业领导者应采取务实且多管齐下的策略，在加快目标终端用户采用新方案的同时，降低供应链波动带来的风险。首先，应优先考虑模组化产品架构和零件标准化，使组装和服务营运能够在不同生产基地之间灵活转移，无需进行大量的重新认证。这种「面向韧性的设计」方法能够缩短在地化进程，并降低贸易政策变化对营运的影响。

我们透明、以证据为基础的调查方法结合了专家访谈、技术检验和供应链映射，为策略规划者和采购主管提供可操作的见解。

本分析所依据的研究采用了一种混合调查方法，结合了专家访谈、结构化的二手资料审查和跨职能检验。主要研究包括对设备工程师、实验室主任、采购主管和服务经理进行有针对性的访谈，以收集有关营运挑战、实施标准和供应商选择趋势的第一手资料。随后，将这些定性见解与产品文件、专利申请、技术白皮书和监管指南进行交叉比对，以检验技术声明并识别新兴的工程趋势。

本文探讨了技术创新、服务经济和政策趋势如何共同决定自动化核酸合成系统的成功应用。

总而言之，自动化核酸合成仪在现代生命科学工具包中扮演核心角色，该领域正处于技术创新、服务经济和政策主导的供应链趋势交汇点，并迅速发展。平台架构的技术进步，以及对研究、诊断和治疗应用日益增长的需求，正在推动产品在通量、整合能力和生命週期支援等方面实现差异化。同时，近期贸易和政策趋势凸显了供应链韧性和模组化设计对于维持实验室运作连续性的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 自动化核酸合成仪市场：依技术划分

  • 基于列
  • 基于膜的

9. 依处理能力分類的自动化核酸合成仪市场

  • 高通量
  • 低吞吐量

第十章 依产品类型分類的自动化核酸合成仪市场

  • 桌上型合成设备
  • 机器人合成设备

第十一章 自动核酸合成仪市场：依应用划分

  • 反义寡核苷酸合成
  • 基因合成
  • PCR引子合成
  • siRNA合成

第十二章 依最终用户分類的自动化核酸合成仪市场

  • 学术研究机构
  • CRO（受託研究机构）
  • 诊断检查室
  • 製药和生物技术

第十三章 各地区自动化核酸合成仪市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 自动化核酸合成仪市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国自动化核酸合成仪市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国自动化核酸合成仪市场

第十七章 中国全自动核酸合成仪市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Agilent Technologies, Inc.
  • BioAutomation, Inc.
  • Bioneer Corporation
  • BIOSSET Ltd.
  • Biotage AB
  • CEM Corporation
  • Intavis AG
  • K&A Laborgerate GmbH
  • Labmate Scientific LLC
  • MABEAL GmbH
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AE420CB13A55

The Automatic Nucleic Acid Synthesizer Market was valued at USD 465.27 million in 2025 and is projected to grow to USD 509.32 million in 2026, with a CAGR of 9.53%, reaching USD 880.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 465.27 million
Estimated Year [2026] USD 509.32 million
Forecast Year [2032] USD 880.27 million
CAGR (%) 9.53%

An authoritative introduction to automated nucleic acid synthesis technologies and their pivotal role in modern research, clinical diagnostics, and therapeutic development

Automatic nucleic acid synthesizers have transitioned from specialized benchtop curiosities into indispensable instruments for modern life sciences workflows. These platforms automate oligonucleotide production, streamlining the generation of primers, probes, small interfering RNAs, and synthetic genes that underpin research, diagnostics, and therapeutic development. As molecular biology techniques have proliferated across academic, clinical, and industrial settings, the ability to produce custom sequences reliably and on demand has become a core capability for organizations seeking agility and reproducibility.

The current generation of synthesizers emphasizes efficiency, error reduction, and integration with downstream processes. Innovations in reagent chemistry, solid supports, and automation control have reduced hands-on time and improved synthesis fidelity. Consequently, laboratories increasingly evaluate synthesizer performance not only by throughput but by the total workflow impact, including consumable logistics, instrument footprint, and compatibility with automation ecosystems. This evolution has driven manufacturers to differentiate across technology architectures, throughput capabilities, and product typologies to meet the divergent needs of research labs, contract service providers, diagnostics facilities, and pharmaceutical R&D groups.

Moving forward, the interplay between instrument design, consumable ecosystems, and digital controls will determine which solutions best support reproducible, scalable nucleic acid production. Decision-makers must weigh operational priorities, regulatory expectations, and integration requirements when specifying platforms to ensure that investments yield durable productivity gains across projects and teams.

How convergence of miniaturization, modular automation and integrated software is reshaping buyer expectations, supplier strategies and operational models in nucleic acid synthesis

The landscape for automatic nucleic acid synthesizers is undergoing rapid, transformative shifts driven by converging technological, operational, and market forces. Advances in miniaturization and microfluidic control have enabled more compact formats that democratize on-site synthesis, while parallelization and robotics expand capacity for high-throughput discovery workflows. These engineering advances are complemented by improvements in solid-phase chemistries and purification strategies that reduce error rates and broaden the menu of chemistries available to users.

Concurrently, demand patterns are changing: academic and research institutes continue to value flexibility and cost-effectiveness, contract research organizations prioritize scalable throughput and regulatory compliance, diagnostics laboratories require validated SOPs and traceability, and pharmaceutical and biotechnology firms focus on integration with automated discovery pipelines and GMP-compatible workflows. These shifts incentivize manufacturers to offer modular instrument architectures that can evolve with user requirements, supporting both low-throughput bench setups and high-throughput automated lines. At the same time, software capabilities that enable remote monitoring, predictive maintenance, and process analytics are becoming central differentiators that improve uptime and reduce total cost of ownership.

Importantly, the industry is responding to broader ecosystem trends such as the drive toward decentralized manufacturing, the rise of nucleic acid therapeutics, and the adoption of digital laboratory infrastructure. Strategic partnerships between instrument makers, consumable suppliers, and laboratory automation integrators are increasing, fostering bundled solutions that accelerate adoption. Overall, these transformative shifts are redefining buyer expectations, moving the market toward integrated, service-oriented offerings that deliver reproducible output across diverse end users and applications.

Assessment of how recent tariff developments and trade policy shifts in 2025 are reshaping supply chains, procurement timing and manufacturing strategies across nucleic acid synthesizer ecosystems

Policy changes in 2025 relating to tariff regimes have introduced a new layer of complexity for stakeholders in the nucleic acid synthesizer value chain. Tariff adjustments affecting imported components, instrument assemblies and specialized consumables have amplified the attention on supply chain resilience, compelling manufacturers and buyers alike to re-evaluate sourcing strategies and operational buffers. In response, several manufacturers have intensified efforts to localize key supply chains, qualify alternative suppliers across multiple geographies, and increase inventory transparency to mitigate potential lead-time variability.

These tariff-driven dynamics have also influenced procurement timing and contract structures. Organizations with ongoing capital expenditure plans are rethinking fiscal phasing to avoid exposure to incremental duties, while service providers are negotiating longer-term supply agreements to stabilize pricing and availability for clients. For laboratories and contract providers that depend on consumables sourced internationally, the increased import costs have heightened the importance of supplier consolidation and vendor-managed inventory arrangements that smooth operational continuity.

Regulatory and trade policy unpredictability has further incentivized product modularization and component standardization. When component interfaces are standardized, manufacturers can more readily shift assembly or component sourcing to alternate regions without extensive requalification. As a result, design-for-manufacturability and supply-chain-aware engineering have become central to commercial strategy. In the near term, stakeholders should expect sustained attention on tariff risk in procurement evaluations and a continued trend toward geographic diversification of suppliers and assembly operations to reduce exposure to policy fluctuations.

Deep segmentation analysis revealing how technology architecture, end user priorities, application requirements, throughput demands and product typology drive purchasing decisions and product roadmaps

A granular understanding of market segmentation reveals distinct technology and user-driven dynamics that shape product design, service models, and go-to-market tactics. Based on technology, platforms fall into column based architectures and membrane based approaches, each presenting unique trade-offs between synthesis fidelity, cycle time, and ease of scale-up. Column based systems typically emphasize established chemistries and batch consistency, while membrane based designs can provide advantages in throughput and parallelization for certain applications.

Based on end user, the buyer landscape comprises academic and research institutes, contract research organizations, diagnostics laboratories, and pharma and biotech entities; within pharma and biotech, requirements diverge between biotechnology firms focused on rapid iteration and large pharmaceutical companies prioritizing regulatory pathways and scale. These end-user distinctions drive different purchasing rationales: smaller research labs value compact benchtop instruments and ease of use, service providers and CROs emphasize throughput and process robustness, diagnostics facilities require validated workflows and traceability, and larger biopharma organizations seek platforms that can integrate into automated discovery and production pipelines.

Based on application, instruments are applied across antisense oligonucleotide synthesis, gene synthesis, PCR primer synthesis, and siRNA synthesis, each application imposing specific purity, error tolerance, and throughput expectations that influence instrument architecture and consumable design. Based on throughput, solutions are configured for high throughput or low throughput use cases, with high-throughput deployments prioritizing parallelization, automation integration, and consumable logistics, whereas low-throughput installations prioritize flexibility, cost per run, and footprint. Finally, based on product type, offerings range from bench top synthesizers to robotic synthesizers; bench top units support decentralized, on-demand synthesis with rapid turnaround, while robotic systems enable centralized, large-scale operations with automation-driven consistency. These segmentation lenses collectively inform product roadmaps and commercialization strategies, enabling firms to tailor value propositions to discrete user needs and operational constraints.

A comprehensive regional breakdown of adoption drivers, regulatory nuances and commercial strategies shaping demand across the Americas, Europe, Middle East & Africa and Asia-Pacific markets

Regional dynamics exert a significant influence on technology adoption, regulatory expectations, and commercial strategies across the nucleic acid synthesizer landscape. In the Americas, strong presence of academic research hubs, biotechnology clusters and an extensive contract research ecosystem supports demand for both benchtop flexibility and scalable robotic solutions. The regulatory environment and reimbursement pathways in this region further encourage investments in diagnostics and therapeutic discovery, stimulating demand for validated workflows and vendor-supported implementation services.

In Europe, Middle East & Africa, fragmentation of regulatory regimes and diverse laboratory infrastructure create mixed adoption patterns; early-adopter urban centers and national genomics initiatives drive demand for advanced automation, while cost-sensitive markets prioritize compact, lower-footprint equipment and consumable affordability. This regional complexity favors manufacturers that can offer modular solutions and localized support networks to address varying serviceability and validation needs.

Across Asia-Pacific, rapid expansion of life sciences investment, increasing domestic manufacturing capabilities, and government-led biotechnology initiatives are accelerating uptake of both high-throughput automated lines and versatile bench top systems. Regional supply chain development and component manufacturing hubs also create strategic opportunities for firms that pursue localization strategies. Taken together, regional differences in funding mechanisms, regulatory expectations, and industrial policy shape product positioning, after-sales support models, and partnership strategies for vendors operating across these territories.

Competitive intelligence and strategic positioning insights revealing how product ecosystems, partnerships and aftermarket services define winning plays for instrument manufacturers and integrators

Competitive dynamics in the automatic nucleic acid synthesizer arena reflect a balance between established instrument portfolios and agile entrants that emphasize software, consumables, and service differentiation. Leading vendors maintain competitive moats through integrated consumable ecosystems, validated protocols, and global support footprints that reduce adoption friction for regulated environments. Meanwhile, emerging firms focus on niche technical innovations such as microfluidics, novel solid supports, or user-centric software that accelerates time-to-result for specific applications.

Strategic behavior increasingly centers on ecosystem plays: manufacturers align with consumable suppliers, software providers, and automation integrators to deliver turnkey solutions that minimize integration risk for customers. Partnerships and co-development agreements are common, enabling cross-validation of reagents and instruments to meet diagnostic and therapeutic quality requirements. At the same time, companies are investing in aftermarket services such as remote diagnostics, preventive maintenance contracts, and consumable subscription models that generate recurring revenue and deepen customer relationships.

Intellectual property portfolios and regulatory know-how are key differentiators for firms targeting pharmaceutical and diagnostics customers; the ability to support validation, traceability, and documentation for regulated workflows enhances competitiveness with large institutional buyers. Ultimately, success depends on combining robust technical performance with scalable service delivery and a clear value proposition for diverse end users, from single-lab adopters to centralized contract manufacturing facilities.

Actionable strategic recommendations for manufacturers, suppliers and institutional buyers to enhance resilience, differentiate service offerings and accelerate adoption across diverse end users

Industry leaders should adopt pragmatic, multi-pronged strategies that reduce exposure to supply-chain volatility while accelerating adoption among target end users. First, prioritize modular product architectures and component standardization so that assembly and service operations can pivot across production sites without extensive requalification. This design-for-resilience approach shortens the path to localization and reduces the operational impact of trade policy shifts.

Second, invest in integrated service offerings that bundle instrument hardware with validated consumables, remote monitoring, and training programs. By shifting value toward recurring service relationships, vendors can stabilize revenue streams and deliver measurable uptime improvements for customers. Third, develop targeted go-to-market approaches for distinct end users: emphasize ease of use and cost efficiency for academic labs, turnkey automation and compliance support for diagnostics laboratories, and scalable, validated platforms for pharmaceutical and biotech clients. Fourth, accelerate digital enablement by embedding telemetry and analytics capabilities that support predictive maintenance and process optimization; these capabilities reduce total cost of ownership and create differentiation in procurement evaluations.

Finally, cultivate strategic partnerships across reagent suppliers, automation integrators, and local service providers to expand addressable markets and shorten customer implementation timelines. These collaborative arrangements facilitate bundled demonstrations, joint validation exercises, and co-marketing that increase credibility with regulated buyers. Taken together, these recommendations equip industry leaders to navigate near-term policy headwinds while building durable competitive advantage in a rapidly evolving landscape.

Transparent, evidence-based research methodology combining expert interviews, technical validation and supply chain mapping to produce practical insights for strategists and procurement leaders

The research underpinning this analysis employed a hybrid methodology that combined primary expert engagements with structured secondary review and cross-functional validation. Primary research included targeted interviews with instrument engineers, laboratory directors, procurement leads, and service managers to capture firsthand perspectives on operational pain points, adoption criteria, and supplier selection dynamics. These qualitative inputs were triangulated with product documentation, patent filings, technical whitepapers, and regulatory guidance to validate technical claims and identify emerging engineering trends.

Secondary research encompassed a systematic review of peer-reviewed literature, conference proceedings, and public filings to chart recent technological advances in reagent chemistry, solid supports, and automation architectures. Supply chain mapping exercises identified critical component categories and common sourcing geographies, while case study analysis of laboratory deployments provided insight into implementation timelines and service model effectiveness. Throughout the process, iterative validation sessions with industry experts refined assumptions and ensured that conclusions were grounded in practical operational realities.

The methodology prioritized transparency and reproducibility: source material selection focused on primary technical references and domain experts, while analytical frameworks emphasized comparative techno-commercial assessment rather than numeric market sizing. This approach produces insights that are actionable for product strategy, procurement planning, and operational risk management.

Concluding synthesis on how technological innovation, service economics and policy dynamics collectively determine success in automated nucleic acid synthesis deployments

In summary, automatic nucleic acid synthesizers occupy a central role in the modern life sciences toolkit, and the sector is evolving rapidly at the intersection of engineering innovation, service economics, and policy-driven supply chain dynamics. Technological advances in platform architectures, coupled with growing demand across research, diagnostic and therapeutic applications, are driving product differentiation along axes of throughput, integration capability, and lifecycle support. At the same time, recent trade and policy developments have underscored the need for supply chain resilience and modular design to sustain uninterrupted laboratory operations.

For stakeholders across the value chain, the path forward requires balancing near-term risk mitigation with long-term strategic investments. Manufacturers should prioritize modularity and service-led offerings to capture recurring value, while buyers should emphasize supplier qualification, validation support, and integration compatibility when selecting platforms. Partnerships that align instrument makers with consumable vendors and automation integrators will accelerate deployment and reduce adoption friction for regulated environments. Ultimately, organizations that combine technical rigor with operational foresight will be best positioned to convert instrument capability into reproducible, cost-effective outcomes for research and clinical workflows.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automatic Nucleic Acid Synthesizer Market, by Technology

  • 8.1. Column Based
  • 8.2. Membrane Based

9. Automatic Nucleic Acid Synthesizer Market, by Throughput

  • 9.1. High Throughput
  • 9.2. Low Throughput

10. Automatic Nucleic Acid Synthesizer Market, by Product Type

  • 10.1. Bench Top Synthesizer
  • 10.2. Robotic Synthesizer

11. Automatic Nucleic Acid Synthesizer Market, by Application

  • 11.1. Antisense Oligonucleotide Synthesis
  • 11.2. Gene Synthesis
  • 11.3. PCR Primer Synthesis
  • 11.4. siRNA Synthesis

12. Automatic Nucleic Acid Synthesizer Market, by End User

  • 12.1. Academic And Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Diagnostics Laboratories
  • 12.4. Pharma And Biotech

13. Automatic Nucleic Acid Synthesizer Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Automatic Nucleic Acid Synthesizer Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Automatic Nucleic Acid Synthesizer Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Automatic Nucleic Acid Synthesizer Market

17. China Automatic Nucleic Acid Synthesizer Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Agilent Technologies, Inc.
  • 18.6. BioAutomation, Inc.
  • 18.7. Bioneer Corporation
  • 18.8. BIOSSET Ltd.
  • 18.9. Biotage AB
  • 18.10. CEM Corporation
  • 18.11. Intavis AG
  • 18.12. K&A Laborgerate GmbH
  • 18.13. Labmate Scientific LLC
  • 18.14. MABEAL GmbH
  • 18.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COLUMN BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COLUMN BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COLUMN BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY MEMBRANE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY MEMBRANE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY MEMBRANE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY HIGH THROUGHPUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY HIGH THROUGHPUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY HIGH THROUGHPUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY LOW THROUGHPUT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY LOW THROUGHPUT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY LOW THROUGHPUT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY BENCH TOP SYNTHESIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY BENCH TOP SYNTHESIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY BENCH TOP SYNTHESIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ROBOTIC SYNTHESIZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ROBOTIC SYNTHESIZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ROBOTIC SYNTHESIZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PCR PRIMER SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PCR PRIMER SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PCR PRIMER SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY SIRNA SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY SIRNA SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY SIRNA SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PHARMA AND BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PHARMA AND BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PHARMA AND BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. GCC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 108. GCC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. GCC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GCC AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. G7 AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 126. G7 AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. G7 AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. NATO AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 132. NATO AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. NATO AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NATO AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY THROUGHPUT, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA AUTOMATIC NUCLEIC ACID SYNTHESIZER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)